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Background: Ventilator-associated pneumonia (VAP) is a leading hospital acquired infection in intensive care units
despite improved patient care practices and advancements in endotracheal tube (ETT) designs. The ETT provides a
conduit for bacterial access to the lower respiratory tract and a substratum for biofilm formation, both of which
lead to VAP. A novel microscopic ordered surface topography, the Sharklet micro-pattern, has been shown to
decrease surface attachment of numerous microorganisms, and may provide an alternative strategy for VAP
prevention if included on the surface of an ETT. To evaluate the feasibility of this micro-pattern for this application,
the microbial range of performance was investigated in addition to biofilm studies with and without a mucin-rich
medium to simulate the tracheal environment in vitro.
Methods: The top five pathogens associated with ETT-related pneumonia, Methicillin-Resistant Staphylococcus
aureus (MRSA), Pseudomonas aeruginosa, Klebsiella pneumonia, Acinetobacter baumannii, and Escherichia coli, were
evaluated for attachment to micro-patterned and un-patterned silicone surfaces in a short-term colonization assay.
Two key pathogens, MRSA and Pseudomonas aeruginosa, were evaluated for biofilm formation in a nutrient rich
broth for four days and minimal media for 24 hours, respectively, on each surface type. P. aeruginosa was further
evaluated for biofilm formation on each surface type in a mucin-modified medium mimicking tracheal mucosal
secretions. Results are reported as percent reductions and significance is based on t-tests and ANOVA models of log
reductions. All experiments were replicated at least three times.
Results: Micro-patterned surfaces demonstrated reductions in microbial colonization for a broad range of species,
with up to 99.9% (p < 0.05) reduction compared to un-patterned controls. Biofilm formation was also reduced, with
67% (p = 0.12) and 52% (p = 0.05) reductions in MRSA and P. aeruginosa biofilm formation, respectively. Further, a
58% (p < 0.01) reduction was demonstrated on micro-patterned surfaces for P. aeruginosa biofilms under clinically-
simulated conditions when compared to un-patterned controls.
Conclusions: This engineered micro-pattern reduces the colonization and biofilm formation of key VAP-associated
pathogens in vitro. Future application of this micro-pattern on endotracheal tubes may prevent or prolong the
onset of VAP without the need for antimicrobial agents.
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Figure 1 Scanning electron micrograph of the Sharklet
micro-pattern cast into silicone. This is the micro-pattern used in
this study (Scale bar = 20 μm).
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Pneumonia is the most common hospital-acquired infec-
tion (HAI) in Intensive Care Units (ICUs)—comprising
some 27% of these infections and driving more than half of
the antibiotics prescriptions in the ICU [1,2]. Ventilator-
associated pneumonia (VAP) is a leading HAI in ICUs, ac-
counting for 86% of nosocomial pneumonia cases [2,3].
The annual U.S. hospital cost of VAP-related treatment
is about $1.5 billion and death rates are between 25-
60% [4,5]. Approximately 80% of all VAP cases are
caused by the ESKAPE pathogens (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acineto-
bacter baumannii, Pseudomonas aeruginosa, and Entero-
bacter species), which are largely responsible for HAIs
and are the primary organisms demonstrating antimicro-
bial resistance, thereby escaping the effects of antibacterial
drugs [6,7]. Current epidemiology shows that S. aureus, P.
aeruginosa, K. pneumoniae, E. coli, and A. baumannii
cause 28%, 22%, 10%, 7% and 7%, respectively, of first
episode VAP and HAI-associated pneumonia infec-
tions world-wide making them the top five causative
agents of these infections [7]. Methicillin-resistant S. aureus
(MRSA) and P. aeruginosa comprise the top two causative
organisms of VAP and are considered particularly devasta-
ting lung pathogens as they cause persistent pneumonia in-
fections, are resistant to a number of antimicrobials, and
are associated with a high attributable mortality of patients
with VAP [7].
VAP is attributed to the endotracheal tube (ETT) used
during ventilation [1,2,5,8]. Intubation does not allow
cough reflexes that clear organisms descending from the
proximal oropharynx to the distal bronchi [5], therefore
the tube provides bacteria access to the lower respiratory
tract via contaminated secretions [9]. Also, the surfaces
of an ETT provide bacteria with a substratum that pro-
motes microbial colonization and biofilm formation
[10-13]. Pathogens isolated from ETT biofilms have been
shown to be the same causative organisms responsible
for the patient’s VAP, which associates the biofilm pres-
ence on the ETT with infection [14,15]. It has been
demonstrated that these biofilms can develop on the
inner and outer surfaces of the ETT in less than 24 hours
of patient intubation [16], and it has been determined
that mature biofilm presence rather than duration of in-
tubation is directly related to occurrence of VAP [17].
Treatments for VAP universally include the use of an-
timicrobials to clear the infection. Prescribing the appro-
priate antimicrobials at the onset of VAP is increasingly
difficult but extremely important, as an inadequate initial
antimicrobial therapy is associated with increased mor-
tality [2,18]. Numerous factors contribute to treatment
decisions (e.g. clinical presentation, local drug resistance
patterns, patient exposure) and this complexity prevents
the standardization of a VAP antimicrobial treatmentguideline [19,20]. Broad-spectrum antimicrobials are
often initially implemented to reduce the risk of patient
mortality. Unfortunately, this path contributes to in-
creased cost and complications for the patient as well as
heightened risk for antimicrobial resistance [2,21]. It is
also well known that the presence of antibiotics induces
robust biofilm formation of a range of pathogens, which
may further contribute to the onset of VAP [22-24].
Common ICU and VAP pathogen drug resistance is stead-
ily rising and outpacing new drug development, leaving
healthcare professionals defenseless against these common
infections.
To prevent the overuse of anti-microbial treatments,
device modifications and improved patient care practices
have been implemented to reduce microbial access to the
lower respiratory tract. The addition of a subglottal secre-
tion port as well as reducing the thickness of the ETT cuff
prevents microaspiration of subglottal secretions into the
lungs. These device modifications, in addition to elevation
of the patient’s head, daily sedation interruptions, and oral
antiseptic treatments, have shown some benefit [5], but
the rate of VAP remains substantial. While there is some
clinical evidence that silver-coated tubes reduce infection
rates [25,26], the cost remains prohibitively high for wide-
spread adoption. A novel solution that would continue to
limit bacterial presence in the lower respiratory tract,
thereby improving patient outcomes, without promoting
antimicrobial resistance is warranted.
Engineered surface topographies, particularly geometries
of ordered features designed with unique roughness prop-
erties, elicit specific, predictable biological responses and
have been shown to control bio-adhesion [27-29]. Studies
have shown that the Sharklet micro-pattern (Figure 1) is
the most effective among ordered topographies (pillars,
channels, other geometries) for inhibiting bio-adhesion
[30]. This shark skin-inspired micro-topography may
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has been shown to inhibit E. coli and S. aureus biofilm for-
mation in vitro without the use of antimicrobial agents
[31,32]. The aim of the present study was to determine
the effectiveness of this ordered micro-pattern, compared
to un-patterned control surfaces, in combating the top five
VAP causative pathogens by assessing microbial colo-
nization and biofilm formation on both surface types in
simplified and clinically simulated in vitro conditions.
Methods
Sample fabrication
Micro-patterned-surface samples and un-patterned (con-
trol) surface samples were created as described previously
[31]. Briefly, silicon wafer molds were created by transfer-
ring the Sharklet pattern design to photoresist-coated sili-
con wafers through photolithography and the features
were deep reactive ion etched to a depth of 3 μm before
being cleaned and methylated prior to use. Smooth, un-
etched silicon wafers were used to create the un-patterned
controls. Dow Corning Silastic T-2 poly-(dimethyl silox-
ane) elastomer films were cast off the silicon wafer molds
by mixing one part by weight curing agent with ten parts
by weight resin, degassing under vacuum, pressing to
0.4 mm thick with glass plates over the silicon wafer
molds, and curing for 1 hour at 65°C. Each flat 0.4 mm
thick silicone film was then punched into 12 mm diameter
circular samples and tested as described below.
Bacterial strains, media, and growth conditions
All clinical isolates analyzed in this study were pur-
chased from ATCC (Table 1). These strains include
clinically isolated strains of MRSA, P. aeruginosa, K.
pneumoniae, A. baumannii and E. coli. Two additional
strains of P. aeruginosa were also assessed to confirm
the validity of the results across multiple strains within a
species: a second clinical isolate and a laboratory strain.
The laboratory P. aeruginosa strain PA14, carrying a ΔbifA












MRSA ATCC700698 5E + 07 1 3 or 4
P. aeruginosa ATCC9027 5E + 06 4 4
P. aeruginosa ATCC10197 5E + 06 4 4
P. aeruginosa PA14ΔbifA 1E + 07 4 4
E. coli ATCC700336 5E + 07 4 4
K. pneumoniae ATCC27799 5E + 07 4 4
A. baumannii ATCC19606 1E + 07 2 4strain control due to its genetic modification to overpro-
duce exopolysaccharide and thus form biofilms quickly
and consistently [33]. A single colony of each organism,
plated on tryptic soy agar (TSA; Criterion), was used to in-
oculate tryptic soy broth (TSB; Criterion) and grown in a
shaking incubator at 37°C and 280 rpm overnight.
Colonization assay for the top five VAP-associated
pathogens
Micro-patterned and un-patterned control samples were
suctioned to the bottom of a sterile Petri dish around
the outer perimeter of the dish using ethanol. Overnight
microbial cultures were sub-cultured and grown to early
log phase in TSB before centrifuging aliquots and resus-
pending cell pellets with 1x phosphate buffered saline
(PBS; CulGeneX). Samples were immersed in inoculum
containing ~107 CFU/mL for incubation time of 1 to
4 hours statically at room temperature depending on the
propensity of the species to colonize the surface; the cell
density on un-patterned controls was targeted to remain
within an average of 2.5 to 6 logs (Table 1). After incu-
bation, the inoculum suspension was decanted and sam-
ples were rinsed three times by adding sterile 1xPBS to
the dish, rotating for 10 seconds on an orbital shaker set
to 80 rpm, and decanting the rinsate. The outer edge of
each sample was removed to minimize the variability
caused by the un-patterned sidewalls by using a sterile
8 mm biopsy punch (VWR International); the 8 mm
samples were then aseptically loaded into a 15 mL con-
ical tube containing 2 mL sterile Dey-Engley broth (Sigma
Aldrich). Attached cells were removed and disaggregated
from each sample surface by vortexing for 30 seconds, son-
icating for 2 minutes in a bath sonicator (Branson 3510)
and vortexing an additional 30 seconds [34]. Samples were
enumerated by a 10-fold dilution series, plating each dilu-
tion onto TSA, and counting the colony forming units
(CFU) after sufficient growth at 37°C overnight. Each CFU
per sample data point was log10 transformed before statis-























3 5.83 3.72 0.05
3 2.78 1.22 0.53
4 3.62 2.26 1.94
3 3.96 1.72 0.44
8 3.51 1.21 0.57
4 4.93 2.01 1.57
3 2.74 0.88 0.32
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conducted for each organism is shown in Table 1. All ex-
periments, except one MRSA experiment, contained four
samples per surface type; that MRSA experiment contained
three samples per surface type (Table 1). Statistical analysis
took place across the three or more experiments for each
organism as described below.
Biofilm assays
Micro-patterned and un-patterned control samples were
suctioned to the bottom of a sterile Petri dish around
the outer perimeter of the dish using ethanol. For MRSA
biofilms: Overnight cultures of MRSA (ATCC700698)
were diluted into fresh TSB to a final bacterial concen-
tration of 106 CFU/mL in TSB. Samples were immersed
with 20 mL of the bacterial suspension statically at 37°C
for four days, with gentle media replenishing each day
from the center of the dish. For P. aeruginosa biofilms:
Overnight cultures of P. aeruginosa ATCC9027 and P.
aeruginosa PA14ΔbifA were diluted into minimal M63
media supplemented with 0.4% arginine (22 mM KH2PO4,
40 mM K2HPO4, 15 mM (NH4)2SO4, 1 mM MgSO4), or
minimal M63 media supplemented with 0.4% arginine,
2 mg/mL porcine mucin that contains the MucA/B com-
plex found in mucus (Sigma Aldrich), and 400 μg/mL oxa-
cillin (Sigma Aldrich), to a final bacterial concentration of
106 CFU/mL [33,35-37]. Samples were immersed with
20 mL of the bacterial suspension statically at 37°C for
24 hours. All dishes were gently rinsed ten times through
media exchange by removing 10 mL media from the cen-
ter of the dish and adding 10 mL sterile 1x PBS. Samples
were fixed for 30 minutes in 2.5% gluteraldehyde (Electron
Microscopy Sciences) and dehydrated with an ethanol de-
hydration exchange series (final ethanol concentrations of
25, 50, 75, and 95%). One to three samples were stained
with propidium iodide and image stacks were obtained in
two to five pre-selected sites per sample by confocal laser
scanning microscopy (Zeiss LSM 510 META on Axiovert
200 M). Semi-volumetric analysis was achieved by totaling
biofilm area coverage in the x-y plane for each image
through the z-stack using ImageJ software after threshold-
ing the image at the brightest frame in the stack [38]. Each
biofilm area coverage/image data point was log10 trans-
formed before statistical analysis. All biofilm experi-
ments were completed in triplicate.
Statistical methods
A log reduction (LR) per experiment was calculated by
subtracting the average log10(micro-pattern data points)
from the average log10(un-patterned control data points).
After confirming the normality of the log reductions by
residual and normal probability plots, the mean log re-
duction was interpreted as the median percent reduction
with the equation: 1-10(− LR). Statistical significance ofthe reductions for the colonization and biofilm assays
were assessed using a 1-sided t-test of log reductions
from at least three experiments per organism. Estimates
of the among- and within-experiment variances were
assessed using ANOVA of the log transformed cell dens-
ities for each un-patterned control sample and micro-
patterned sample, with a random effect for experiment.
The repeatability standard deviation (SD) of the un-
patterned sample, which quantifies the repeatability of
the methods based on control variances, is the square
root of the sum of the among-experiment variance and
the within-experiment variance divided by the number
of replicates per experiment [39]. All analyses were per-
formed using the statistical software MiniTab16.
Results
Colonization assay for the top five VAP-associated
pathogens
Bacterial colonization on micro-patterned and un-patterned
surfaces were evaluated for the top five respiratory path-
ogens associated with VAP, including clinically isolated
strains of MRSA, P. aeruginosa, K. pneumoniae, A.
baumannii and E. coli. Two additional strains of P.
aeruginosa were also evaluated to confirm the validity of
the results across multiple strains within a species: a
second clinical isolate and a laboratory, hyper-biofilm
forming strain. The micro-patterned surface signifi-
cantly reduced the colonization of all species and strains
compared to un-patterned controls, with median reduc-
tions in CFU counts ranging from 95.6% to 99.9%, p < 0.05
when evaluated across multiple experiments (Figure 2). To
confirm the consistency of the methods used to obtain
these results, the repeatability SD of the log10(CFU/control
sample) was calculated across experiments for each or-
ganism (Table 1). Except for P. aeruginosa ATCC10197
and K. pneumoniae, all un-patterned repeatability SDs
were close to or below 0.50 log, a historical benchmark
that indicates highly reproducible colonization on con-
trols across multiple experiments [40]. Even with the in-
creased variability observed for P. aeruginosa ATCC10197
and K. pneumoniae, the micro-patterned surfaces main-
tained strong statistically significant performance in this
assay thereby indicating good repeatability of the log re-
ductions for all of the organisms tested (Figure 2).
Biofilm formation of MRSA and P. aeruginosa on the
micro-pattern
Biofilms were grown on micro-patterned and un-
patterned surfaces for MRSA and two strains of P. aeru-
ginosa followed by confocal imaging and ImageJ analysis
to quantify the bacterial area coverage for each image in
the z-stacks. The micro-patterned surface showed a 67%
(p = 0.123) median reduction of MRSA biofilm volumes
grown over a four day duration in a TSB media when
Figure 2 The micro-patterned surface significantly reduces the
colonization of the five microbial species most frequently
associated with VAP when compared to un-patterned controls.
All mean log reductions (across at least three experiments) are
statistically significantly positive by single t-test *p < 0.05; **p≤ 0.01.
Error bars are the standard error of the mean log reduction.
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Similar observations were seen for the hyper-biofilm
forming strain P. aeruginosa PA14ΔbifA, where a signi-
ficant 52% median reduction in volume (p = 0.05) was
observed (Figure 3). Importantly, mature biofilms [17]
were obtained on the un-patterned control surfaces forFigure 3 The micro-pattern reduces biofilm formation of two key VAP
un-patterned controls. The P. aeruginosa (ATCC 9027) strain did not form
P. aeruginosa PA14ΔbifA strains showed 67% (p = 0.123) and 52% (p = 0.05)
A representative image per surface type for each organism was selected to
images taken through the biofilm (Scale bar = 20 μm).both the MRSA and P. aeruginosa PA14ΔbifA strains,
whereas bacterial colonization on the micro-patterned
surfaces was more dispersed (Figure 3). When quantifying
the resemblance of the biofilm volume measurements
on un-patterned controls, the repeatability SDs of the
log-transformed biofilm coverage data was 0.081 for the
PA14ΔbifA experiments and 0.681 for the MRSA exper-
iments. While the level of acceptable variability of image
analysis data has not been established, the small SDs for
PA14ΔbifA indicates high consistency in biofilm forma-
tion on the un-patterned controls. The P. aeruginosa
ATCC 9027 strain did not form a sufficient quantity of
biofilm under these non-clinical conditions to accurately
quantify biofilm volume coverage, as most image coor-
dinates had no depth from which to obtain image stacks
(Figure 3).
Biofilm reduction of P. aeruginosa in a mucin-modified
medium
The P. aeruginosa clinical isolate ATCC 9027 did not form
biofilms in the simplified minimal medium (Figure 3), so
additional studies on this strain were conducted in a
medium that would both encourage biofilm formation
and simulate the clinical environment of the lungs. Thus,
a mucin-rich minimal medium supplemented with oxa-
cillin was used to promote biofilm and provide the mucin
glycoproteins that make up the main component of the
mucus present in the lungs [22-24,35,36]. This medium-related pathogens, MRSA and P. aeruginosa when compared to
robust biofilms under these conditions, however the MRSA and the
median reductions in biofilm compared to controls, respectively.
reflect quantitative results. Images obtained by compiling the stack of
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ical isolate on the un-patterned control surfaces, whereas
the micro-patterned surfaces maintained an inhibitory
effect, with a 58% reduction compared to controls (p =
0.009) (Figure 4). The repeatability SD for biofilms on
controls across three experiments was low at 0.11, sug-
gesting that the methodology used in these assays ob-
tains repeatable biofilm growth and coverage.
Discussion
Innovative solutions for VAP-prevention via ETT device
modifications will be critical for improved patient care,
as VAP accounts for 86% of hospital-acquired pneumo-
nia cases in ICUs [2,3]. Recent studies have shown that
biofilm development on the surfaces of an ETT is a
strong predictor of VAP, with biofilms forming in as lit-
tle as 24 hours. Current device modifications have had
some success in reducing infection rates, particularly
cuff modifications that limit microbial access to the
lower respiratory tract. However, further limiting micro-
bial access to the lower respiratory tract is crucial for re-
ducing VAP rates in patients. The goal of this study was
to determine the feasibility of using a novel micro-
patterned surface to decrease microbial colonization for
the top five VAP pathogens, and biofilm formation for
the top two, under simulated ETT environments.
It is known that surface characteristics modulate mi-
crobial interactions – however this is the first study that
has shown performance of a specific, ordered micro-Figure 4 The micro-pattern significantly reduces P. aeruginosa (ATCC
average of 58% (p = 0.009) over three separate experiments. A represe
randomly as all images were similar within each experiment. Images obtain
(Scale bar = 20 μm).pattern against the colonization of the top five organisms
that are associated with VAP and other HAIs. Current lit-
erature shows that this micro-pattern reduces S. aureus
and E. coli biofilms [31,32], however P. aeruginosa, an-
other common biofilm former, had not been tested. This
study evaluated the top two causative agents of VAP in
biofilm growth assays and showed a reduction of both
MRSA and P. aeruginosa mature biofilm volume cover-
age on micro-patterned surfaces when compared to un-
patterned controls. Before this study, it was unknown
whether biologically relevant proteins, like MucA/B that
make up the mucus found in the lungs [36], would coat
the micro-pattern and interfere with its capability to re-
duce microbial colonization. Therefore, P. aeruginosa was
further challenged in a lung secretion-like mucin medium
supplemented with antibiotics, and the micro-pattern
demonstrated statistically significant biofilm reduction
even under these more challenging conditions. Together,
these data contribute to our understanding of the range
of bacterial inhibition exhibited by this novel micro-
pattern against several clinically relevant pathogens and
conditions.
As investigated elsewhere, the theoretical basis for the
topography’s function is its ability to create a stable non-
wetting state where air pockets at key points in the
microscopic features are maintained, thereby inhibiting
interaction of microbes with the surface [41]. Specifically,
potential attachment sites that would generally induce
stable interactions of micro-organisms to the surface are9027) biofilm formation in a mucin-rich environment by an
ntative image per surface type from each experiment was selected
ed by compiling the stack of images taken through the biofilm
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wetting nature of the topography. This non-wetting prop-
erty is enhanced by the use of specific nanoforce gradients
that occur based on the sizes of the microscopic features,
which create an energetically unstable surface to which
the micro-organisms are unable to formulate stable at-
tachment modes [42].
A specific growth media formulation and antibiotics
were used in this study to achieve clinically simulated
biofilm growth in vitro. Robust and accelerated P.
aeruginosa biofilm growth was obtained by using an
arginine minimal media to encourage microbial respir-
ation in this biofilm model [43], and to induce a sessile
lifestyle that promotes biofilm formation [44]. The nu-
trient rich mucin protein complex, in addition to antibi-
otics, have been shown to enhance biofilm formation
[22,35,36] and both were included in the medium to in-
duce robust biofilm formation and provide a simulated
clinical environment [19]. The combined result was accel-
erated biofilm formation on control surfaces within
24 hours for P. aeruginosa – a goal commonly met by
other biofilm reactor systems [45,46].
The biofilms present on un-patterned control surfaces
in this study were three-dimensional and made up of
large cellular aggregates, which were in contrast to the
single cell or small aggregates observed on the micro-
patterned surface. Given this observation, implementation
of the micro-pattern onto the surface of an ETT could
provide a synergistic effect together with the human im-
mune system and antibiotic treatments to clear potentially
harmful bacteria before they form a biofilm and cause an
infection. Should such a result be demonstrated in a cli-
nical trial, it would ultimately lead to decreased use of
antimicrobial treatments and silver-coated ETTs, that may
contribute to the rise in antimicrobial resistance observed
in the ESKAPE pathogens.
Future work will include demonstrating the efficacy of
this micro-pattern in advanced multi-species in vitro bio-
film models with air-flow and animal VAP models [47-49]
utilizing ETT prototypes with the micro-pattern on the
inner and outer tube surfaces. These complex models
would further our understanding of tissue compatibility
and performance of the pattern in clinically relevant
environments, before conducting clinical trials that
would evaluate patient driven outcomes. Since ventilator-
associated complications (VAC) are equally important in
prolonging patient recovery [50], future studies will assess
the capability of the micro-pattern to reduce tube occlu-
sion, an interesting hypothesis based on the general anti-
wetting capability of the micro-patterned surface [51,52].
As this technology has not yet been clinically evaluated,
our current results do not indicate what outcomes we
can expect for patients who use a micro-patterned ETT.
Nonetheless, with future research we hope to develop amicro-patterned ETT that reduces microbial colonization
and biofilm formation associated with VAP as well as tube
occlusion that leads to VAC. Once demonstrated to be ef-
fective in clinical studies, this micro-patterned ETT, com-
bined with state-of-the art device cuff designs and bundle
practices, may supply clinicians with an arsenal to dimin-
ish VAP and VAC rates.
Conclusions
The micro-pattern surface modification inhibits the at-
tachment of MRSA, P. aeruginosa, K. pneumoniae, E.
coli, and A. baumannii, the top five VAP-associated
pathogens, by up to 99.9% when compared to un-
patterned controls. The micro-pattern also inhibits the for-
mation of MRSA and P. aeruginosa biofilms, the latter of
which was further investigated in a complex mucin-rich
medium mimicking the tracheal environment. Demonstra-
tion of biofilm reduction by this micro-patterned surface in
a range of conditions and with a range of pathogens suggest
that the micro-pattern implemented onto ETT surfaces
may reduce VAP rates without the use of antimicrobial
agents.
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